Francisco Xavier Elisarraras

Dr. Francisco Xavier Elisarraras


Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 March 2025 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
IGIlana Golub
Ilana Golub
ATAbhinav Thummala
Abhinav Thummala
TMTyler Morad
Tyler Morad
JDJasmeet S. Dhaliwal
Jasmeet S. Dhaliwal
FEFrancisco Xavier Elisarraras
Francisco Xavier Elisarraras
GCGeoffrey Weiting Cho
Geoffrey Weiting Cho
Cardiovascular disease (CVD) is a leading cause of death, accounting for over 30% of annual global fatalities. Ischemic heart disease, in turn, is a frontrunner of worldwide CVD mortality. With the burden of coronary disease rapidly growing, understanding the nuances of cardiac imaging and risk prognostication becomes paramount. Myocardial perfusion imaging (MPI) is a frequently utilized and well established testing modality due to its significant clinical impact in disease diagnosis and risk assessment. Recently, nuclear cardiology has witnessed major advancements, driven by innovations in novel imaging technologies and improved understanding of cardiovascular pathophysiology. Applications of artificial intelligence (AI) to MPI have enhanced diagnostic accuracy, risk stratification, and therapeutic decision-making in patients with coronary artery disease (CAD). AI techniques such as machine learning (ML) and deep learning (DL) neural networks offer new interpretations of immense data fields, acquired through cardiovascular imaging modalities such as nuclear medicine (NM). Recently, AI algorithms have been employed to enhance image reconstruction, reduce noise, and assist in the interpretation of complex datasets. The rise of AI in nuclear medicine (AI-NM) has proven itself groundbreaking in the efficiency of image acquisition, post-processing time, diagnostic ability, consistency, and even in risk-stratification and outcome prognostication. To that end, this narrative review will explore these latest advances in AI in nuclear medicine and its rapid transformation of the cardiac diagnostics landscape. This paper will examine the evolution of AI-NM, review novel AI techniques and applications in nuclear cardiac imaging, summarize recent AI-NM clinical trials, and explore the technical and clinical challenges in its implementation of artificial intelligence.

5 March 2026 in JACC: Case Reports
Verified
Journal Article
Open access
FEFrancisco Xavier Elisarraras
Francisco Xavier Elisarraras
RPRobert A. Pelberg
Robert A. Pelberg
JRJacob S. Roberts
Jacob S. Roberts
JSJay A. Shah
Jay A. Shah
JXJeffrey Xia
Jeffrey Xia
GCGeoffrey Cho
Geoffrey Cho
IgG4-related disease (IgG4-RD) is a systemic fibroinflammatory disorder with multiorgan involvement, including increasingly recognized cardiovascular manifestations such as aortitis and periarteritis. Coronary involvement remains rare and is often clinically silent and poorly characterized, with most reported cases associated with pericoronary inflammation, ectasia, or aneurysmal dilation rather than diffuse high-risk atherosclerosis. A 63-year-old man with longstanding IgG4-RD presented with abdominal pain and no cardiac symptoms. Computed tomography demonstrated periaortic inflammation, incidental coronary calcification, and markedly elevated serum IgG4. Coronary computed tomography angiography revealed diffuse pericoronary thickening without aneurysmal dilation. Advanced plaque analysis showed an extreme coronary plaque burden dominated by lipid-rich necrotic core and noncalcified plaque, consistent with high-risk atherosclerosis. This case expands the spectrum of IgG4-related coronary involvement, demonstrating diffuse, severe, inflammation-associated atherosclerosis without ectasia or aneurysm and highlighting the disconnect between symptoms and disease burden, with potential for silent, high-risk coronary disease. IgG4-RD may harbor clinically silent but high-risk coronary disease, supporting vigilance, proactive coronary imaging, aggressive immunosuppression, and intensive secondary prevention.